Assessment of platelet activation in myeloproliferative disorders with complementary techniques

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 3, 2004, Pages 235-240

  Bermejo, Emilse ^a   Alberto, Maria F ^a   Meschengieser, Susana S ^a   Lazzari, Maria A ^a  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

Author keywords

Activated platelets; Aggregation; Flow cytometry; Myeloproliferative disorders; Storage pool disease

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CD63 ANTIGEN; FIBRINOGEN; PADGEM PROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL LABELING; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FUNCTION TEST; HISTOCHEMISTRY; HUMAN; HUMAN CELL; MALE; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; TECHNIQUE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTHEMIA;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NEPHELOMETRY AND TURBIDIMETRY; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 2342435362     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200404000-00006     Document Type: Article

References (30)

1. Schafer AI. Bleeding and thrombosis in myeloproliferative disorders. Blood 1984; 64:1-12.
2. Leone G, Sica S, Chiusolo P, Teofili L, De Stefano V. Blood cells diseases and thrombosis. Haematologica 2001; 86:1236-1244.
3. Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost 1997; 78:617-621.
4. Wehmeier A, Schafer AL, Frike S, Schneider W. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelets disorders to clinical aspects of disease. Haemostasis 1989; 19:251-259.
5. Pareti FI, Gugliotta L, Mannucci L, Guarani A, Mannucci PM. Biochemical and metabolic aspects of platelet dysfunction in myeloproliferative disorders. Thromb Haemost 1982; 47:84-89.
6. Rendu F, Lebret M, Nurden A, Caen JP. Detection of an acquired platelet storage pool disease in three patients with myeloproliferative disorders. Thromb Haemost 1979; 42:794-795.
7. Caranobe C, Sie P, Fernandez F, Pris J, Moatti S, Boneu B. Abnormal platelet serotonin uptake and binding sites in myeloproliferative disorders. Thromb Haemost 1984; 51:349-353.
8. Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbach HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 2000; 110:116-124.
9. Wu KK. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Int Med 1972; 88:7-11.
10. Manoharan A, Gemmell R, Brighton T, Dunkey S, Lopez K, Kyle P. Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies. Br J Haematol 1999; 105:618-625.
11. Balduini CL, Bertolino G, Noris P, Piletta GC. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am J Clin Pathol 1991; 95:82-86.
12. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194:927-929.
13. Feinman RD, Lubowsky J, Charo IF, Zabinski MP. The lumiaggregometer: a new instrument for simultaneous measurement of secretion and aggregation. J Lab Clin Med 1977; 90:125-130.
14. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelet in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70:307-315.
15. Warkentin TE, Powling MJ, Hardisty RM. Measurement of fibrinogen binding to platelet in whole blood by flow cytometry: a micromethod for detection of platelet activation. Br J Haematol 1990; 76:387-394.
16. Adelman B, Carlson P, Handin RI. Evaluation of platelets surface antigens by fluorescence flow cytometry. Methods Enzymol 1992; 125:420-427.
17. Wehmeier A, Tschöpe D, Esser J, Manzel C, Nieuwenhuis HK, Schneider W. Circulating activated platelets in myeloproliferative disorders. Thromb Res 1991; 61:271-278.
18. Metzelaar MJ, Sixma JJ, Nieuwenhuis HK. Detection of platelets activation using activation specific monoclonal antibodies. Blood Cells 1990; 16:85-93.
19. Sarah L, Janes SL, Wilson DJ, Chronos N, Goodall AH. Evaluation of whole blood flow cytometric detection of platelet bound fibrinogen on normal subjects and patients with activated platelets. Thromb Haemost 1993; 70:659-666.
20. Gordon N, Thom J, Cole C, Baker R. Rapid detection of hereditary and acquired platelet storage pool deficiency by flow cytometry. Br J Haematol 1995; 89:117-123.
21. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999; 36:9-13.
22. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics. Lyon: World Health Organization, IARC Press; 2001.
23. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981; 58:916-919.
24. Le Blanc K, Lindhal T, Rosendahl K, Samuelson J. Impaired platelet binding of fibrinogen due to a lower number of GPIIb-IIIa receptors in polycythemia vera. Thromb Res 1998; 91:287-295.
25. Mistry R, Cahill M, Chapman C, Wood JK, Barnett DB. I-fibrinogen binding to platelets in myeloproliferative disease. Thromb Haemost 1991; 66:529-533.
26. Nurden P, Bihour C, Smith M, Raymond JM, Nurden AT. Platelet activation and thrombosis: studies in a patient with essential thrombocythemia. Am J Hematol 1996; 51:79-84.
27. Meschengieser S, Blanco A, Woods A, Maugeri N, Fernandez J, Dupont J, Lazzari MA. Intraplatelet levels of vWF:Ag and fibrinogen in myeloproliferative disorders. Thromb Res 1987; 48:311-319.
28. Mazzucato M, Marco LD, Angelis VD, Roia DD, Bizzarro N, Casonato A. Platelet membrane abnormalities in myeloproliferative disorders: decrease in glycoprotein Ib and IIb/IIIa complex is associated with deficient receptor function. Br J Haematol 1989; 73:369-374.
29. Cahill MR, Macey MG, Newland AC. Correlation of GP53 and P-selectin expression in myeloproliferative disorders and normal controls. Blood Coagul Fibrinolysis 1996; 7:169-171.
30. Wehmeier A, Sudhoff T, Meierkord F. Relation of latelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Semin Thromb Hemost 1997; 23:391-402.